Open AccessTransarterial chemoembolization and bland embolization for hepatocellular carcinoma
Author(s) -
Emmanuel Tsochatzis,
Evangelia Fatourou,
James O’Beirne,
Tim Meyer,
Andrew K. Burroughs
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i12.3069
Subject(s) - hepatocellular carcinoma , medicine , embolization , transarterial embolization , radiology , chemotherapy , carcinoma , stage (stratigraphy) , randomized controlled trial , surgery , paleontology , biology
Transarterial chemoembolization (TACE) is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth. Despite its widespread use, TACE remains an unstandardized procedure, with variation in type and size of embolizing particles, type and dose of chemotherapy and interval between therapies. Existing evidence from randomized controlled trials suggest that bland transarterial embolization (TAE) has the same efficacy with TACE. In the current article, we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use.